Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Briacell Therap stock logo
BCTX
Briacell Therap
$0.82
+6.5%
$3.03
$0.69
$29.40
$5.57M1.27734,862 shs3.02 million shs
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$1.88
+13.3%
$1.27
$0.62
$5.01
$31.81M1.722.32 million shs2.64 million shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.43
+0.3%
$3.34
$2.57
$6.88
$21.20M0.629,053 shs1,758 shs
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$3.93
+11.3%
$3.65
$2.85
$19.00
$6.45M0.03243,842 shs47.99 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Briacell Therap stock logo
BCTX
Briacell Therap
-61.88%-73.54%-75.32%-82.81%-94.48%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
+7.79%+46.90%+37.19%+55.14%+124.32%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+0.59%+3.01%-1.13%+24.36%-39.25%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-2.95%+4.40%-3.48%+8.84%-81.48%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Briacell Therap stock logo
BCTX
Briacell Therap
1.8756 of 5 stars
3.52.00.00.02.40.00.6
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
2.4311 of 5 stars
3.73.00.00.02.70.00.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.4601 of 5 stars
0.04.00.00.03.31.70.6
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Briacell Therap stock logo
BCTX
Briacell Therap
3.00
Buy$32.003,792.47% Upside
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
3.33
Buy$14.00644.68% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest QLGN, MIRA, NAII, and BCTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2025
Briacell Therap stock logo
BCTX
Briacell Therap
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/A($2.20) per shareN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/A$0.13 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$4.98M1.29N/AN/A($4.12) per share-0.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Briacell Therap stock logo
BCTX
Briacell Therap
-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$7.85M-$0.51N/AN/AN/AN/A-341.08%-272.93%8/12/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/25/2025 (Estimated)
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-$6.26MN/A0.00N/AN/AN/AN/A8/13/2025 (Estimated)

Latest QLGN, MIRA, NAII, and BCTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025N/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.10N/AN/AN/AN/AN/A
6/13/2025Q3 2025
Briacell Therap stock logo
BCTX
Briacell Therap
-$1.76-$1.64+$0.12-$1.64N/AN/A
5/14/2025Q1 2025
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.15-$0.11+$0.04-$0.11N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Briacell Therap stock logo
BCTX
Briacell Therap
N/AN/AN/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Briacell Therap stock logo
BCTX
Briacell Therap
N/A
3.41
3.41
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A
12.86
12.86
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A
2.33
2.33
CompanyEmployeesShares OutstandingFree FloatOptionable
Briacell Therap stock logo
BCTX
Briacell Therap
86.78 million6.39 millionOptionable
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
216.92 million15.80 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
501.64 million1.61 millionNot Optionable

Recent News About These Companies

Qualigen Therapeutics, Inc. (QLGN) - Yahoo Finance
Qualigen Therapeutics to participate in next funding round for NanoSynex
Qualigen to participate in next funding round for NanoSynex

New MarketBeat Followers Over Time

Media Sentiment Over Time

Briacell Therap stock logo

Briacell Therap NASDAQ:BCTX

$0.82 +0.05 (+6.49%)
Closing price 04:00 PM Eastern
Extended Trading
$0.83 +0.01 (+1.08%)
As of 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

MIRA Pharmaceuticals stock logo

MIRA Pharmaceuticals NASDAQ:MIRA

$1.88 +0.22 (+13.25%)
Closing price 04:00 PM Eastern
Extended Trading
$1.84 -0.03 (-1.86%)
As of 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.41 -0.01 (-0.41%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Qualigen Therapeutics stock logo

Qualigen Therapeutics NASDAQ:QLGN

$3.93 +0.40 (+11.33%)
Closing price 04:00 PM Eastern
Extended Trading
$3.92 -0.01 (-0.13%)
As of 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.